Research Analysts Set Expectations for ImmunoPrecise Antibodies Ltd.’s Q1 2025 Earnings (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of ImmunoPrecise Antibodies in a report issued on Monday, September 18th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.07) EPS and Q4 2025 earnings at ($0.05) EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its quarterly earnings data on Monday, July 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The business had revenue of $4.15 million during the quarter, compared to the consensus estimate of $4.45 million. ImmunoPrecise Antibodies had a negative return on equity of 35.22% and a negative net margin of 95.81%.

ImmunoPrecise Antibodies Price Performance

NASDAQ:IPA opened at $1.79 on Tuesday. ImmunoPrecise Antibodies has a 52-week low of $1.71 and a 52-week high of $5.90. The business’s fifty day moving average is $2.28 and its 200 day moving average is $2.76. The company has a current ratio of 2.45, a quick ratio of 2.10 and a debt-to-equity ratio of 0.16.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bank of Montreal Can bought a new stake in ImmunoPrecise Antibodies during the second quarter valued at approximately $668,000. Ingalls & Snyder LLC grew its position in ImmunoPrecise Antibodies by 9.1% during the 1st quarter. Ingalls & Snyder LLC now owns 1,058,035 shares of the company’s stock worth $2,931,000 after acquiring an additional 87,888 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in ImmunoPrecise Antibodies by 12.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 27,661 shares of the company’s stock worth $146,000 after purchasing an additional 3,088 shares during the period. Finally, Bank of America Corp DE lifted its position in ImmunoPrecise Antibodies by 1,849.1% in the first quarter. Bank of America Corp DE now owns 57,517 shares of the company’s stock valued at $295,000 after purchasing an additional 54,566 shares during the last quarter. 5.71% of the stock is owned by institutional investors.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.